Patent number: 6448293
Abstract: A compound of general formula (I), or pharmaceutically acceptable salts, solvates or polymorphs thereof; wherein; R1 and R2, which may be the same or different, are hydrogen, C1-C6alkyl, (CH2)m (C3-C6cycloalkyl) wherein m =0, 1, 2 or 3, or R1 and R2 together with the nitrogen to which they are attached form an azetidine ring; each R3 is independently CF3, OCF3, C1-4alkylthio or C1-C4alkoxy; n is 1, 2 or 3; and R4 and R5, which may be the same or different, are: A—X, wherein A =—CH=CH— or —(CH2)p— where p is 0, 1 or 2; X is hydrogen, F, Cl, Br, I, CONR6R7, SO2NR6R7, SO2NHC(=O)R6, OH, C1-4alkoxy, NR8SO2R9, NO2, NR6R11, CN, CO2R10, CHO, SR10, S(O)R9 or SO2R10; R6, R7, R8 and R10 which may be the same or different, are hydrogen or C1-6alkyl optionally substituted independently by one or more R12; R9 is C1-6 alkyl optionally substituted independently by one or more R12; R11 is hydrogen, C1-6 alkyl optionally substituted independently by one or more R12, C(O
Type:
Grant
Filed:
March 16, 2001
Date of Patent:
September 10, 2002
Assignee:
Pfizer Inc.
Inventors:
Mark David Andrews, David Hepworth, Donald Stuart Middleton, Alan Stobie
Patent number: 6369069
Abstract: The invention relates to compounds of the formula (I),
in which the symbols have the following meaning:
R(1) is
1. alkyl having 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms;
2. alkyl having 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms, in which one to all hydrogen atoms are replaced by fluorine;
3. alkenyl having 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12 carbon atoms; or
4. —CnH2n−nn—Y,
nn is zero or 2; and
n is zero, 1, 2, 3 or 4; where n is unequal to zero or 1 if nn is equal to 2;
5. —CnH2n−nn—Y,
nn is zero or 2; and
n is 1, 2, 3 or 4; where n is unequal to 1 if nn is equal to 2.
Type:
Grant
Filed:
August 4, 2000
Date of Patent:
April 9, 2002
Assignee:
Aventis Pharma Deutschland GmbH
Inventors:
Heinz-Werner Kleemann, Hans-Jochen Lang, Jan-Robert Schwark, Andreas Weichert, Sabine Faber, Hans-Willi Jansen, Stefan Petry